Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 178

Sort by

Sort Order Select

Journal Articles

Novel agents and immune invasion in Hodgkin lymphoma

Reid W. Merryman, Ann LaCasce

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 243–248.

https://doi.org/10.1182/hematology.2019000029

Published: 2019

Journal Articles

Opportunities for immunotherapy in childhood acute myeloid leukemia

Adam J. Lamble, Sarah K. Tasian

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 218–225.

https://doi.org/10.1182/hematology.2019000357

Published: 2019

Journal Articles

Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment

Scott F. Huntington

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 252–259.

https://doi.org/10.1182/hematology.2019000030

Published: 2019

Journal Articles

Indolent lymphomas: pushing the pace with novel agents

Caron A. Jacobson

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 279–286.

https://doi.org/10.1182/hematology.2019000032

Published: 2019

Journal Articles

What's new in the prevention and treatment of cancer-associated thrombosis?

Miriam Kimpton, Marc Carrier

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 158–166.

https://doi.org/10.1182/hematology.2019000023

Published: 2019

Journal Articles

Evidence-Based Minireview: What is the optimal timing of anti–PD-1 antibodies in relapsed classical Hodgkin lymphoma?

Pamela Blair Allen, Ann S. LaCasce

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 249–251.

https://doi.org/10.1182/hematology.2019000077

Published: 2019

Journal Articles

The growing landscape of FLT3 inhibition in AML

Catherine C. Smith

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 539–547.

https://doi.org/10.1182/hematology.2019000058

Published: 2019

Journal Articles

Single-agent and combination biologics in acute myeloid leukemia

Guillaume Richard-Carpentier, Courtney D. DiNardo

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 548–556.

https://doi.org/10.1182/hematology.2019000059

Published: 2019

Journal Articles

Inflammatory bone marrow microenvironment

Nils B. Leimkühler, Rebekka K. Schneider

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 294–302.

https://doi.org/10.1182/hematology.2019000045

Published: 2019

Journal Articles

Navigating the nexus of MRD and novel agents in ALL

Anjali S. Advani, Edward A. Copelan

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 9–16.

https://doi.org/10.1182/hematology.2019000008

Published: 2019

Journal Articles

Molecular profiling and management of mantle cell lymphoma

Jia Ruan

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 30–40.

https://doi.org/10.1182/hematology.2019000011

Published: 2019

Journal Articles

Microbiota modification in hematology: still at the bench or ready for the bedside?

Christopher J. Severyn, Ryan Brewster, Tessa M. Andermann

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 303–314.

https://doi.org/10.1182/hematology.2019000365

Published: 2019

Journal Articles

Management of older Hodgkin lymphoma patients

Andrew M. Evens, Jordan Carter, Kah Poh Loh, Kevin A. David

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 233–242.

https://doi.org/10.1182/hematology.2019000028

Published: 2019

Journal Articles

Moving immunotherapy into the front line in ALL

Amanda Winters, Lia Gore

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 209–217.

https://doi.org/10.1182/hematology.2019000017

Published: 2019

Journal Articles

Curing Ph + ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant

Adele K. Fielding

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 24–29.

https://doi.org/10.1182/hematology.2019000010

Published: 2019

Journal Articles

Selecting Frontline Therapy for CLL in 2018

Nitin Jain

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 242–247.

https://doi.org/10.1182/asheducation-2018.1.242

Published: 2018

Journal Articles

Where does PD-1 blockade fit in HL therapy?

Alex F. Herrera

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 213–220.

https://doi.org/10.1182/asheducation-2018.1.213

Published: 2018

Journal Articles

Novel therapies for relapsed/refractory aggressive lymphomas

Jonathon B. Cohen

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 75–82.

https://doi.org/10.1182/asheducation-2018.1.75

Published: 2018

Journal Articles

Using genomics to define pediatric blood cancers and inform practice

Rachel E. Rau, Mignon L. Loh

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 286–300.

https://doi.org/10.1182/asheducation-2018.1.286

Published: 2018

Journal Articles

Risk-adapted therapy for advanced-stage Hodgkin lymphoma

Michael A. Spinner, Ranjana H. Advani

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 200–206.

https://doi.org/10.1182/asheducation-2018.1.200

Published: 2018

NARROW

Novel agents and immune invasion in Hodgkin lymphoma

Opportunities for immunotherapy in childhood acute myeloid leukemia

Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment

Indolent lymphomas: pushing the pace with novel agents

What's new in the prevention and treatment of cancer-associated thrombosis?

Evidence-Based Minireview: What is the optimal timing of anti–PD-1 antibodies in relapsed classical Hodgkin lymphoma?

The growing landscape of FLT3 inhibition in AML

Single-agent and combination biologics in acute myeloid leukemia

Inflammatory bone marrow microenvironment

Navigating the nexus of MRD and novel agents in ALL

Molecular profiling and management of mantle cell lymphoma

Microbiota modification in hematology: still at the bench or ready for the bedside?

Management of older Hodgkin lymphoma patients

Moving immunotherapy into the front line in ALL

Curing Ph + ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant

Selecting Frontline Therapy for CLL in 2018

Where does PD-1 blockade fit in HL therapy?

Novel therapies for relapsed/refractory aggressive lymphomas

Using genomics to define pediatric blood cancers and inform practice

Risk-adapted therapy for advanced-stage Hodgkin lymphoma

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only